Katie Kosko

DocwireNews

Personalized response-based adaptive radiation therapy (RT) with concurrent chemotherapy provided excellent tumor control while minimizing rates of high-grade toxicities in patients with locally advanced non-small cell lung cancer (NSCLC), showed a study published in the International Journal of Radiation Oncology, Biology&ndash;Physics.The phase 2 study was conducted at the University of Michigan, and it included 47 patients who had received a diagnosis of stage IIA-III unresectable NSCLC.&ldquo;Local failure rates after treatment for locally advanced NSCLC remain high,&rdquo; the researchers said. &ldquo;Efforts to improve local control with uniform dose-escalation or dose-escalation to mid-treatment PET-avid residual disease have been limited by heightened toxicity.&rdquo;Therefore, the researchers sought to improve local tumor control and reduce toxicity by using functional imaging, fluorodeoxyglucose-positron emission tomography (FDG-PET) and ventilation/perfusion single photon emission computerized tomography (V/Q SPECT).Imaging was conducted before treatment and again during treatment to help predict treatment outcomes and how well the lung functions during treatment. Blood and urine samples were also collected to investigate any markers that might determine the patient&rsquo;s risk of developing adverse effects from radiation to the lungs.The primary endpoint of the study was grade &ge;2 lung and esophageal toxicities. Time to local progression, tumor response, and overall survival were secondary endpoints.Patients enrolled in the study were a median age of 66 years, mostly white (91%) men (66.4%), and 60% formerly smoked. The patients received concurrent chemoradiation with personalized RT over 30 fractions incorporating FDG-PET and V/Q SPECT.Based on mid-treatment FDG-PET, the final 9 fractions were adapted up to a total of 80.4 Gy. Patients who did not progress then went onto receive consolidative carboplatin/paclitaxel or durvalumab (Imfinzi).The study showed that response-based adaptive RT reduced the rates of high-grade esophagitis and pneumonitis. At 1 year after treatment, the rates of grade 2 and grade 3 pneumonitis were 21.3% and 2.1%, respectively. There was no difference in pneumonitis rates among patients who received and did not receive adjuvant durvalumab (P=0.74).Grade 2 esophagitis was seen in 66% of the patients. However, there were no grade 3 esophageal-related toxicities.Moreover, the 1- and 2-year local control rates were 94.5% and 87.5%, respectively. Overall survival was 82.8% at the 1-year mark and 62.3% at 2 years.&ldquo;Response-based adaptive dose-escalation accounting for tumor change and normal tissue function during treatment provided excellent local control, comparable toxicity to standard chemoradiation, and did not increase toxicity with adjuvant immunotherapy,&rdquo; the researchers said.Source: <a href="https://www.redjournal.org/article/S0360-3016(24)00749-1/abstract" target="_blank" rel="noopener">IJROBP</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Phase 2 Study Evaluates Response-Based Adaptive Radiotherapy for NSCLC

Non-Small Cell Lung Cancer

Personalized response-based adaptive radiation therapy (RT) with concurrent chemotherapy provided excellent tumor control while minimizing rates of high-grade toxicities in NSCLC.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe